MedTrace Logo

Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

NCT01838902 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 467

Last updated 2018-03-22

No results posted yet for this study

Summary

In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers compared to the recommended dose of primaquine but with a decreased risk of haemolysis.

Children (\> 1 year) and adults with normal Glucose-6-phosphate dehydrogenase enzyme levels but with asexual Plasmodium falciparum parasites on the day of screening will be invited to take part in this study.

Conditions

Interventions

DRUG

DHA-PPQ

Participants will receive a 3 day course of DHA-PPQ

DRUG

PQ (0.75)

Participants will receive a single dose of PQ at 0.75mg base/kg body weight

DRUG

PQ (0.4)

Participants will receive a single dose of PQ at 0.4mg base/kg body weight

DRUG

PQ (0.2)

Participants will receive a single dose of PQ at 0.2mg base/kg body weight

Sponsors & Collaborators

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Umberto D'Alessandro, MD, PhD · MRC Unit, Fajara The Gambia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-02-28
Completion
2015-10-31

Countries

  • The Gambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838902 on ClinicalTrials.gov